Atlas Trials

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Clinical trial NCT06745687 · RECRUITING

Trial details

NCT number
NCT06745687
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
High Risk Smoldering Multiple Myeloma
Start date
2024-12-30
Primary completion
2027-08-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.